Long-term Ibuprofen and Aspirin Use Linked to Lower Alzheimer’s Risk
By Jessica Freeborn on March 13, 2025 — Fact checked by Jill Seladi-Schulman, Ph.D.
Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and aspirin may significantly reduce the risk of developing dementia, according to a recent study. These commonly used medications, while primarily used for pain relief, have been shown to have potential benefits against serious cognitive decline.
Key Points:
- NSAIDs may reduce inflammation, playing a crucial role in dementia development.
- Study analyzed data from 11,745 participants, finding long-term NSAID use lowered dementia risk.
- Short-term or intermediate NSAID use was associated with a slight increase in dementia risk.
How Does NSAID Use Impact Dementia Risk?
The study, published in the Journal of the American Geriatrics Society, highlighted the relationship between NSAIDs and inflammation, which may be crucial in understanding dementia risk. Participants in the analysis were aged around 66 years old, with regular screenings performed to detect dementia.
Long-Term NSAID Use Linked to Lower Dementia Risk
With an average follow-up time of about 14.5 years, researchers discovered that about 81.3% of participants used NSAIDs. Notably, users of NSAIDs that do not lower beta-amyloid-42 levels appeared to have a greater reduction in all-cause dementia risk.
“The study suggests chronic inflammation could contribute significantly to neurodegeneration,” says Dr. Vernon Williams, a sports neurologist.
Study Limitations
While findings are promising, the study had limitations, including a lack of diversity among participants and reliance on observational data without random assignment. Additionally, the study could not establish a direct cause-and-effect relationship.
What Could This Mean for Clinical Practice?
This research could signal changes in how NSAIDs are utilized in clinical settings. However, no one should start taking NSAIDs without consulting healthcare professionals.
Opinion & Analysis
Overall, the evidence hinting at the protective effect of NSAIDs against dementia is compelling. Yet, further research, including controlled trials, is essential to confirm these results and better understand the implications for patients at risk of cognitive decline.
For a deeper dive into this study and its implications, check out the full article
A desk review of Scrimba in October 2026: 74 courses with 25 of them free, three co-built with MDN, four career paths with published hour counts, the new Explain feature, and a Terms of Service... A complete 2026 guide to the RadioMaster radio controller range: 27 models from $34.99 to $399.99, the MT12 surface radio, ER-series receivers and factory-direct warranty. <p>Seven Visme alternatives priced from each vendor’s own page: Canva, Piktochart, Venngage, Beautiful.ai, Infogram, Adobe Express and the free fallbacks — plus where Visme still wins.</p> QUICK VERDICT. ElevenLabs pricing runs from $0 to $990 a month, but convert it to cost per minute of audio and the ladder collapses: $0.20/min on Starter, $0.18 on Creator, $0.165 on Pro and still... Trezor built the first hardware wallet in 2013, and thirteen years later it is still the most transparent company in the category. That transparency has a consequence most reviews skip: because Trezor publishes what researchers...related products
